You're watching...
Array Biopharma CEO Ron Squarer on partnering with pharmaceutical companies and new drugs in the pipeline.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
-- month.
Well -- -- Biopharma the stock up 50% since may it's up a 150%.
Year over year.
A -- a small drug company partnership some of the biggest global pharma companies fronts where is the CEO -- any joins me now from -- so.
The stock performance as Donna -- you've got some big big big partners -- you've got.
We got Lilly Roche Amgen Genentech most of these are cancer therapies.
Heavy government approach to actually do doesn't have been a more of a strategic deal with the latest companies -- -- take over.
Well I've been more issue of great integrity beyond -- you this morning and -- -- -- we've been seeing tremendous some momentum not only in our partner products which you've been referred to some of those great partnerships but also and our wholly owned.
Portfolio and we see tremendous runway go looking for for our company and we're just focused on that getting products that post marketing ultimately commercializing them at this point.
OK OK so at this point is let's stick with the partnerships -- -- from but at the same time huge used to -- Glaxo.
You worked at buys are obviously those are not on the list that we just put -- there are those potential partners for you right now.
You know we have already some of the greatest partners in the industry -- with both AstraZeneca and Novartis are probably -- to -- with the possibility of entering.
About last stage of development before registration and commercialization.
With these -- they're too great cancer products.
But we have eight more partnerships behind them.
And so we I think we've done very well thus far in partnering with these great companies are helping us to move forward.
We do they'll have four products in the clinic that are wholly owned and we'd like to take victory to cancer products forward.
As far as we can on her -- ultimately planning for commercialization.
That we have a couple in came and asked whether we're looking to partner.
And we're going to be partnering those to help fuel our cancer focused.
OK that's the new paid that's that's a RY 797 -- -- -- pain.
Drug that's currently in trials that that's gonna compete with Mexico don't cracked.
Well it's pretty remarkable to brand new mechanism minutes -- incredible results in that we tested it.
On top of and -- which you're familiar with their very commonly use that this.
Products like Celebrex -- commonly used.
And we sort of very -- her focus once -- to work on top event sets and that we actually did and we worked better than the arm that was using just and sets and placebo we did an active arm with -- auction code -- in there.
-- two to have some sort of comparison study wasn't designed to compare directly but what we found is that our product actually work similarly in patients who could complete the trial Mexico don't.
I -- to go to the problem is about 40% of the patients had dropped off vs on 797.
Most education stayed on.
Because they've built but it never thought I'd do it ask you about the other very exciting their -- have gotten to have been you have coming up the pipeline it's obviously -- to treatment.
Blood cancer I had pre leukemia guesses as -- the -- the layman's term for this one -- 614.
This new drug is is hopefully going to be coming through clinical trials for -- right.
Well we'd like to see it -- and serve these pivotal trials.
Sometime during next year as our data emerges.
You know it's amazing because it we're focusing on on that early states are called a low risk in one patients.
In -- classic syndrome and after they failed current therapies they have absolutely no choice.
In terms of therapy and what we've shown in when given 614.
Almost 40% of patients that therapeutic -- are seeing improvements in these very very tough these devastating -- to logic conditions this is a deadly disease.
I'm the prognosis in the population that we are studying is very severe very very short lifespan for these patients.
So we're looking forward to seeing our new formulation which is much more potent -- -- early next year and we'd like see this product to eventually I helping patients survive.
Robin what can update then -- square operate pharmaceutical thank you very much I appreciate it.
Great to have you and we be be glad to be back to give you an update on a frog.
